Skip to main content
Back
Watch Compare

VYNE Therapeutics Inc.

Data quality: 100%
VYNE
Nasdaq Manufacturing Chemicals
$0.61
▼ $0.00 (-0.41%)
Mkt Cap: 20.66 M
Price
$0.62
Mkt Cap
20.66 M
Day Range
—
52-Week Range
—
Volume
—
Open —
50D / 200D Avg
—
50D / 200D Avg
—

Quick Summary

Key Takeaways

Revenue declined -55.67% annually over 5 years
Debt/Equity of 0.00 — conservative balance sheet
Negative free cash flow of -33.12 M
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 69.44%

Growth

Revenue Growth (5Y)
-55.67%
Below sector avg (1.82%)
Revenue (1Y)13.77%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
-63.80%
Below sector avg (-53.41%)
ROIC-56.62%
Net Margin-4646.14%
Op. Margin-5219.12%

Safety

Debt / Equity
0.00
Below sector avg (0.31)
Current Ratio7.60
Interest CoverageN/A

Valuation

PE (TTM)
-0.78
Above sector avg (-1.48)
P/B Ratio0.53
EV/EBITDAN/A
Dividend YieldN/A

Price History

Financial Trends

Peer Comparison

vs Manufacturing sector median (1364 peers)
Metric Stock Sector Median
P/E -0.8 -1.5
P/B 0.5 1.6
ROE % -63.8 -53.4
Net Margin % -4646.1 -41.5
Rev Growth 5Y % -55.7 1.8
D/E 0.0 0.3

All Fundamental Metrics
Growth
Revenue Growth (1Y) 13.77% Revenue Growth (3Y) 15.95%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -55.67% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 570,000.0 Net Income (TTM) -26.48 M
ROE -63.80% ROA -52.37%
Gross Margin N/A Operating Margin -5219.12%
Net Margin -4646.14% Free Cash Flow (TTM) -33.12 M
ROIC -56.62% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.00 Current Ratio 7.60
Interest Coverage N/A Asset Turnover 0.01
Working Capital 38.51 M Tangible Book Value 38.88 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0.78 Forward P/E N/A
P/B Ratio 0.53 P/S Ratio 36.25
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -160.33%
Market Cap 20.66 M Enterprise Value -1.39 M
Per Share
EPS (Diluted TTM) -0.62 Revenue / Share 0.02
FCF / Share -0.99 OCF / Share -0.99
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 125.08%
SBC-Adj. FCF -36.14 M Growth Momentum 69.44

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 570,000.0 501,000.0 424,000.0 477,000.0 14.76 M
Net Income -26.48 M -39.83 M -28.45 M -23.21 M -73.33 M
EPS (Diluted) -0.62 -0.93 -2.78 -7.28 1.42
Gross Profit — — — — —
Operating Income -29.75 M -43.64 M -29.26 M -34.30 M -68.03 M
EBITDA — — — — —
R&D Expenses 19.24 M 30.95 M 16.31 M 18.39 M 24.96 M
SG&A Expenses — — — 16.39 M 54.48 M
D&A 23,000.0 4,000.0 0.0 72,000.0 109,000.0
Interest Expense — — — 0.0 5.61 M
Income Tax 4,000.0 4,000.0 0.0 13,000.0 -448,000.0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 30.16 M 66.91 M 97.69 M 40.76 M 67.05 M
Total Liabilities 2.40 M 14.82 M 8.95 M 9.35 M 18.41 M
Shareholders' Equity 27.77 M 52.09 M 88.74 M 31.20 M 48.64 M
Total Debt 0.0 0.0 0.0 0.0 0.0
Cash & Equivalents 24.03 M 19.93 M 30.62 M 30.91 M 42.25 M
Current Assets 30.01 M 64.44 M 95.96 M 38.28 M 63.19 M
Current Liabilities 2.40 M 14.82 M 7.54 M — 18.41 M